View in EDS HTML Full Text PDF Full Text

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.

Saved in:
Bibliographic Details
Title: A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
Authors: Zhang T; Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina., Harrison MR; Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina., O'Donnell PH; University of Chicago, Chicago, Illinois., Alva AS; University of Michigan Medical Center, Ann Arbor, Michigan., Hahn NM; Johns Hopkins University, Baltimore, Maryland., Appleman LJ; University of Pittsburgh, Pittsburgh, Pennsylvania., Cetnar J; Oregon Health and Science University Center for Health, Portland, Oregon., Burke JM; Rocky Mountain Cancer Centers, Aurora, Colorado., Fleming MT; Virginia Oncology Associates, Norfolk, Virginia., Milowsky MI; Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina., Mortazavi A; Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Shore N; Carolina Urologic Research Center, Myrtle Beach, South Carolina., Sonpavde GP; Dana-Farber Cancer Institute, Boston, Massachusetts., Schmidt EV; Merck & Co, Inc, North Wales, Pennsylvania., Bitman B; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California., Munugalavadla V; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California., Izumi R; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California., Patel P; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California., Staats J; Division of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, North Carolina., Chan C; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina., Weinhold KJ; Division of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, North Carolina., George DJ; Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.; Duke Clinical Research Institute, Durham, North Carolina.
Source: Cancer [Cancer] 2020 Oct 15; Vol. 126 (20), pp. 4485-4497. Date of Electronic Publication: 2020 Aug 05.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32757302
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zhang+T%22">Zhang T</searchLink>; Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.<br /><searchLink fieldCode="AU" term="%22Harrison+MR%22">Harrison MR</searchLink>; Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.<br /><searchLink fieldCode="AU" term="%22O'Donnell+PH%22">O'Donnell PH</searchLink>; University of Chicago, Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Alva+AS%22">Alva AS</searchLink>; University of Michigan Medical Center, Ann Arbor, Michigan.<br /><searchLink fieldCode="AU" term="%22Hahn+NM%22">Hahn NM</searchLink>; Johns Hopkins University, Baltimore, Maryland.<br /><searchLink fieldCode="AU" term="%22Appleman+LJ%22">Appleman LJ</searchLink>; University of Pittsburgh, Pittsburgh, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Cetnar+J%22">Cetnar J</searchLink>; Oregon Health and Science University Center for Health, Portland, Oregon.<br /><searchLink fieldCode="AU" term="%22Burke+JM%22">Burke JM</searchLink>; Rocky Mountain Cancer Centers, Aurora, Colorado.<br /><searchLink fieldCode="AU" term="%22Fleming+MT%22">Fleming MT</searchLink>; Virginia Oncology Associates, Norfolk, Virginia.<br /><searchLink fieldCode="AU" term="%22Milowsky+MI%22">Milowsky MI</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina.<br /><searchLink fieldCode="AU" term="%22Mortazavi+A%22">Mortazavi A</searchLink>; Ohio State University Comprehensive Cancer Center, Columbus, Ohio.<br /><searchLink fieldCode="AU" term="%22Shore+N%22">Shore N</searchLink>; Carolina Urologic Research Center, Myrtle Beach, South Carolina.<br /><searchLink fieldCode="AU" term="%22Sonpavde+GP%22">Sonpavde GP</searchLink>; Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Schmidt+EV%22">Schmidt EV</searchLink>; Merck & Co, Inc, North Wales, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Bitman+B%22">Bitman B</searchLink>; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Munugalavadla+V%22">Munugalavadla V</searchLink>; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Izumi+R%22">Izumi R</searchLink>; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Patel+P%22">Patel P</searchLink>; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Staats+J%22">Staats J</searchLink>; Division of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, North Carolina.<br /><searchLink fieldCode="AU" term="%22Chan+C%22">Chan C</searchLink>; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.<br /><searchLink fieldCode="AU" term="%22Weinhold+KJ%22">Weinhold KJ</searchLink>; Division of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, North Carolina.<br /><searchLink fieldCode="AU" term="%22George+DJ%22">George DJ</searchLink>; Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.; Duke Clinical Research Institute, Durham, North Carolina.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220374236%22">Cancer</searchLink> [Cancer] 2020 Oct 15; Vol. 126 (20), pp. 4485-4497. <i>Date of Electronic Publication: </i>2020 Aug 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0374236 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-0142 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220008543X%22">0008543X </searchLink><i>NLM ISO Abbreviation: </i>Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32757302
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/cncr.33067
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 4485
    Titles:
      – TitleFull: A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zhang T
      – PersonEntity:
          Name:
            NameFull: Harrison MR
      – PersonEntity:
          Name:
            NameFull: O'Donnell PH
      – PersonEntity:
          Name:
            NameFull: Alva AS
      – PersonEntity:
          Name:
            NameFull: Hahn NM
      – PersonEntity:
          Name:
            NameFull: Appleman LJ
      – PersonEntity:
          Name:
            NameFull: Cetnar J
      – PersonEntity:
          Name:
            NameFull: Burke JM
      – PersonEntity:
          Name:
            NameFull: Fleming MT
      – PersonEntity:
          Name:
            NameFull: Milowsky MI
      – PersonEntity:
          Name:
            NameFull: Mortazavi A
      – PersonEntity:
          Name:
            NameFull: Shore N
      – PersonEntity:
          Name:
            NameFull: Sonpavde GP
      – PersonEntity:
          Name:
            NameFull: Schmidt EV
      – PersonEntity:
          Name:
            NameFull: Bitman B
      – PersonEntity:
          Name:
            NameFull: Munugalavadla V
      – PersonEntity:
          Name:
            NameFull: Izumi R
      – PersonEntity:
          Name:
            NameFull: Patel P
      – PersonEntity:
          Name:
            NameFull: Staats J
      – PersonEntity:
          Name:
            NameFull: Chan C
      – PersonEntity:
          Name:
            NameFull: Weinhold KJ
      – PersonEntity:
          Name:
            NameFull: George DJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 10
              Text: 2020 Oct 15
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 1097-0142
          Numbering:
            – Type: volume
              Value: 126
            – Type: issue
              Value: 20
          Titles:
            – TitleFull: Cancer
              Type: main
ResultId 1